The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_Depreciation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_CoreSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_BiotherapeuticSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_ProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=cdxs_SegmentOperatingExpenseAllocationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2018 USD ($) segment	Sep. 30, 2017 USD ($)	Dec. 31, 2017 segment
Segment Reporting Information [Line Items]
Number of operating segments \| segment					2		1
Total revenues	$ 16,946		$ 9,984		$ 44,526	$ 28,301
Cost of product revenue	3,791		3,976		10,228	10,768
Research and development	7,917		8,055		22,464	20,242
Selling, general and administrative	7,344		7,989		22,485	21,141
Total costs and operating expenses	19,052		20,020		55,177	52,151
Loss from operations	(2,106)		(10,036)		(10,651)	(23,850)
Depreciation					(812)	(795)
Loss before income taxes	(1,987)		(10,076)		(10,428)	(23,834)
Stock-based compensation	1,770		1,833		6,207	5,212
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	12,125		9,984		34,019	28,301
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	4,821		0		10,507	0
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	16,946		9,984		44,526	28,301
Cost of product revenue	3,791		3,976		10,228	10,768
Research and development	7,678		7,884		21,842	19,716
Selling, general and administrative	2,035		1,649		6,310	5,238
Total costs and operating expenses	13,504		13,509		38,380	35,722
Loss from operations	3,442		(3,525)		6,146	(7,421)
Stock-based compensation	451		662		2,248	1,824
Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	12,125		9,984		34,019	28,301
Cost of product revenue	3,791		3,976		10,228	10,768
Research and development	4,758		4,410		14,548	12,582
Selling, general and administrative	1,870		1,649		5,695	5,238
Total costs and operating expenses	10,419		10,035		30,471	28,588
Loss from operations	1,706		(51)		3,548	(287)
Stock-based compensation	354		607		2,005	1,670
Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	4,821		0		10,507	0
Cost of product revenue	0		0		0	0
Research and development	2,920		3,474		7,294	7,134
Selling, general and administrative	165		0		615	0
Total costs and operating expenses	3,085		3,474		7,909	7,134
Loss from operations	1,736		(3,474)		2,598	(7,134)
Stock-based compensation	97		55		243	154
Corporate [Member]
Segment Reporting Information [Line Items]
Total costs and operating expenses	5,120		6,310		(15,762)	(15,618)
Depreciation	(309)		(241)		812	795
Product Sales [Member]
Segment Reporting Information [Line Items]
Total revenues	8,405		6,948		18,291	19,134
Product Sales [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	8,405		6,948		18,291	19,134
Product Sales [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0		0		0	0
Product Sales [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	8,405		6,948		18,291	19,134
Product Sales [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	8,405		6,948		18,291	19,134
Product Sales [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0		0		0	0
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	8,541		3,036		26,235	9,167
Research and Development Revenue [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	3,720		3,036		15,728	9,167
Research and Development Revenue [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	4,821		0		10,507	0
Research and Development Revenue [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	8,541		3,036		26,235	9,167
Research and Development Revenue [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	3,720		3,036		15,728	9,167
Research and Development Revenue [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 4,821		$ 0		$ 10,507	$ 0
Segment Operating Expense Allocation [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Research and development		$ 300
Segment Operating Expense Allocation [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Research and development				$ 100